RxDoctor Payments Data

Brian Easton, MD

Family Medicine · Orange, VANPI 1659360592

Payments from drug & device makers

$235in general payments, 2019–2025

Across 13 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$82
  • Pfizer$58
  • Abbott$44
  • AbbVie$38
  • Novo Nordisk$14

What the payments were for

  • Speaking & faculty fees$4519%
  • Food & beverage$19081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis5$82
Pfizer2$58
Abbott2$44
AbbVie(2 entities)3$38
Novo Nordisk1$14

How this compares

$235 in reported general payments places this provider in the 45th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$272,235
Medicare patients
620
Services billed
3,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$163,170
FarxigaDapagliflozin Propanediol50$53,826
JardianceEmpagliflozin45$40,298
OzempicSemaglutide20$28,786
JanuviaSitagliptin Phosphate20$27,239
TrulicityDulaglutide15$23,327
XareltoRivaroxaban27$21,578
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$21,310
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,810
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$8,773
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$8,459
JanumetSitagliptin Phos/Metformin Hcl12$6,907
Breo ElliptaFluticasone/Vilanterol16$6,688
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$6,579
SymbicortBudesonide/Formoterol Fumarate18$4,882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$163,170185 claims
Novo NordiskOzempic$14$28,78620 claims
AbbVieSynthroid$38$1,92826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Orange

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →